(2007) wound healing acceleration Researchers applied topical GHK-Cu formulations to full-thickness dermal wounds in an animal model over 21 days
Regulatory Status AOD-9604 is not FDA-approved for any medical use and is listed by the FDA as a bulk drug substance that may present safety risks. Clinical development was halted after Phase IIb trials failed to meet efficacy endpoints. Summary AOD-9604 is a synthetic analog of the HGH 177191 fragment developed for fat-metabolism research
Users who expect dramatic results in one or two weeks from concentration increases will be disappointed, and may unnecessarily escalate further based on inaccurate assessment
Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake [8] [9]
[DOI] [PMC free article] [PubMed] [Google Scholar] Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J
